| scholarly article | Q13442814 |
| P50 | author | Kenneth A. Freedberg | Q87347438 |
| Benjamin Linas | Q56655086 | ||
| P2093 | author name string | C Robert Horsburgh | |
| Angela Y Wong | |||
| P2860 | cites work | The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States | Q22242768 |
| Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 | ||
| Silicosis-related years of potential life lost before age 65 years - United States, 1968-2005 | Q26206566 | ||
| Long-term mortality after gastric bypass surgery | Q28241874 | ||
| Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis | Q28289915 | ||
| Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay | Q33236625 | ||
| Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine | Q33578537 | ||
| Birth cohort effect on latent tuberculosis infection prevalence, United States | Q33631694 | ||
| Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of Amer | Q33650105 | ||
| Causes and costs of hospitalization of tuberculosis patients in the United States | Q33737994 | ||
| Outcomes of contact investigations of infectious tuberculosis patients | Q33738000 | ||
| Revisiting rates of reactivation tuberculosis: a population-based approach | Q34065641 | ||
| Excess deaths associated with underweight, overweight, and obesity | Q34412581 | ||
| Tuberculosis studies in Muscogee County, Georgia. Twenty-year evaluation of a community trial of BCG vaccination | Q34543090 | ||
| Pulmonary adverse events of anti-tumor necrosis factor-alpha antibody therapy | Q34554043 | ||
| Sensitivity analysis and potential uses of a novel gamma interferon release assay for diagnosis of tuberculosis | Q35073163 | ||
| What is the price of life and why doesn't it increase at the rate of inflation? | Q35186749 | ||
| Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis | Q35953268 | ||
| Use of whole-blood samples in in-house bulk and single-cell antigen-specific gamma interferon assays for surveillance of Mycobacterium tuberculosis infections. | Q36452353 | ||
| Epidemiological basis of tuberculosis eradication. 10. Longitudinal studies on the risk of tuberculosis in the general population of a low-prevalence area | Q36719361 | ||
| HIV and tuberculosis infection in San Francisco's homeless adults. Prevalence and risk factors in a representative sample | Q36735242 | ||
| Comparison of sensitivities of two commercial gamma interferon release assays for pulmonary tuberculosis | Q36747473 | ||
| Assessment of the economic burden of COPD in the U.S.: a review and synthesis of the literature | Q36760100 | ||
| Economic costs of diabetes in the U.S. In 2007. | Q37097601 | ||
| The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis | Q83359788 | ||
| Cost-effectiveness of digital mammography breast cancer screening | Q37143624 | ||
| Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. | Q37767584 | ||
| Controlled chemoprophylaxis trials in tuberculosis. A general review | Q39002300 | ||
| The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods | Q39388568 | ||
| A tuberculin screening and isoniazid preventive therapy program in an inner-city population | Q39483273 | ||
| Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. | Q40007313 | ||
| Results of screening for tuberculosis in foreign-born persons applying for adjustment of immigration status | Q40861809 | ||
| Drug Dependence, A Possible New Risk Factor for Tuberculosis Disease | Q41478554 | ||
| Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. | Q42110466 | ||
| Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis | Q42545892 | ||
| Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial | Q42683018 | ||
| Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. | Q43444643 | ||
| Tuberculosis among foreign-born persons in the United States: achieving tuberculosis elimination | Q44705340 | ||
| Cost-effectiveness of colonoscopy in screening for colorectal cancer | Q44774826 | ||
| Feasibility and reliability of health-related quality of life measurements among tuberculosis patients | Q44885820 | ||
| Comparison of the sensitivity and specificity of two whole blood interferon-gamma assays for M. tuberculosis infection | Q44987069 | ||
| Tuberculosis and substance abuse in the United States, 1997-2006. | Q45931262 | ||
| Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. | Q46588695 | ||
| Longitudinal predictors of injection cessation and subsequent relapse among a cohort of injection drug users in Baltimore, MD, 1988-2000. | Q46858949 | ||
| HIV prevalence estimates--United States, 2006. | Q46880600 | ||
| QuantiFERON-TB Gold in the diagnosis of active tuberculosis | Q47660773 | ||
| Injection drug users in the United States, 1979-2002: an aging population | Q48627430 | ||
| Tuberculosis in a Cohort of Southeast Asian Refugees: A Five-Year Surveillance Study | Q50568538 | ||
| Trends in bariatric surgical procedures. | Q50771061 | ||
| Mortality trends in men and women with diabetes, 1971 to 2000. | Q51102735 | ||
| Health-related quality of life trajectories among adults with tuberculosis: differences between latent and active infection. | Q51112574 | ||
| Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. | Q51227130 | ||
| Measurement of health preferences among patients with tuberculous infection and disease. | Q51701677 | ||
| Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. | Q51797725 | ||
| Mathematical model for the epidemiology of tuberculosis, with estimates of the reproductive number and infection-delay function. | Q52247165 | ||
| Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. | Q52925370 | ||
| Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection | Q56485907 | ||
| Priorities for the Treatment of Latent Tuberculosis Infection in the United States | Q58321668 | ||
| Treatment for latent TB in correctional facilities: a challenge for TB elimination | Q64127214 | ||
| The cost-effectiveness of screening for latent tuberculosis infection | Q64129925 | ||
| Mortality in a cohort of homeless adults in Philadelphia | Q64135344 | ||
| BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life | Q66881435 | ||
| Tuberculosis screening in alcoholics and drug addicts | Q67987628 | ||
| A cost-effectiveness analysis of the routine use of isoniazid prophylaxis in patients with a positive Mantoux skin test | Q68361480 | ||
| Tuberculosis screening in alcoholics and drug addicts | Q69438122 | ||
| Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis | Q71452598 | ||
| Transmission of tuberculosis in San Francisco and its association with immigration and ethnicity | Q73703075 | ||
| Benefits of screening for latent Mycobacterium tuberculosis infection | Q73824469 | ||
| Changes in the transmission of tuberculosis in New York City from 1990 to 1999 | Q74053576 | ||
| Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic | Q74623365 | ||
| Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts | Q82646416 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | United States of America | Q30 |
| tuberculosis | Q12204 | ||
| latent tuberculosis | Q4254929 | ||
| P304 | page(s) | 590-601 | |
| P577 | publication date | 2011-09-01 | |
| P1433 | published in | American Journal of Respiratory and Critical Care Medicine | Q4744267 |
| P1476 | title | Priorities for screening and treatment of latent tuberculosis infection in the United States | |
| P478 | volume | 184 |
| Q38541022 | A Systematic Review of Studies Evaluating the Cost Utility of Screening High-Risk Populations for Latent Tuberculosis Infection |
| Q28081244 | A scoping review of cost-effectiveness of screening and treatment for latent tubercolosis infection in migrants from high-incidence countries |
| Q30446983 | A systematic review and meta-analysis of the impact of tuberculosis on health-related quality of life |
| Q64940957 | A systematic review of economic evaluations of interventions to tackle tuberculosis in homeless people. |
| Q30248823 | A systematic review of economic models used to assess the cost-effectiveness of strategies for identifying latent tuberculosis in high-risk groups |
| Q38601841 | A systematic synthesis of direct costs to treat and manage tuberculosis disease applied to California, 2015. |
| Q42376840 | Burden of non-adherence to latent tuberculosis infection drug therapy and the potential cost-effectiveness of adherence interventions in Canada: a simulation study. |
| Q38048745 | Clinical year in review IV: HIV, mycobacterial disease, pulmonary hypertension, and interstitial lung disease |
| Q41363378 | Comparison of an interferon-gamma release assay and the tuberculin skin test for diagnosis of latent tuberculosis in homeless people in Iran: a cross-sectional study. |
| Q35577840 | Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations |
| Q36161757 | Cost analysis of tuberculin skin test and the QuantiFERON-TB Gold In-tube test for tuberculosis screening in a correctional setting in Dallas, Texas, USA. |
| Q49177335 | Cost effectiveness of interferon-gamma release assay for school-based tuberculosis screening |
| Q35553230 | Cost-Effectiveness of Screening and Treating Foreign-Born Students for Tuberculosis before Entering the United States |
| Q37467519 | Cost-effectiveness of QuantiFERON testing before initiation of biological therapy in inflammatory bowel disease. |
| Q34672436 | Cost-effectiveness of Quantiferon®-TB Gold-in-Tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil |
| Q47640073 | Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model |
| Q33746114 | Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. |
| Q37308287 | Cost-effectiveness of latent tuberculosis screening before steroid therapy for idiopathic nephrotic syndrome in children |
| Q104459146 | Cost-effectiveness of newer technologies for the diagnosis of Mycobacterium tuberculosis infection in Brazilian people living with HIV |
| Q47133419 | Cost-effectiveness of post-landing latent tuberculosis infection control strategies in new migrants to Canada |
| Q36562401 | Decline in tuberculosis among Mexico-born persons in the United States, 2000-2010. |
| Q35495985 | Description of the largest cluster of tuberculosis notified in Norway 1997-2011: is the Norwegian tuberculosis control programme serving its purpose for high risk groups? |
| Q64138098 | Economic analysis of CDC's culture- and smear-based tuberculosis instructions for Filipino immigrants |
| Q35775657 | Effectiveness of reporting on latent tuberculous infection in Massachusetts, 2006-2008 |
| Q41291128 | Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. |
| Q34090979 | Estimating the burden of tuberculosis among foreign-born persons acquired prior to entering the U.S., 2005-2009. |
| Q26746155 | Getting to Zero: Tuberculosis Elimination in California |
| Q35645948 | Health-related quality of life and tuberculosis: a longitudinal cohort study |
| Q34625452 | How methodologic differences affect results of economic analyses: a systematic review of interferon gamma release assays for the diagnosis of LTBI |
| Q38062363 | Implementation of an interferon-gamma release assay to screen for tuberculosis in refugees and immigrants |
| Q35238051 | Increased risk of tuberculosis among foreign-born persons with diabetes in California, 2010-2012. |
| Q37647932 | Insights into redox sensing metalloproteins in Mycobacterium tuberculosis |
| Q37391637 | Integrated screening for tuberculosis and HIV in tuberculosis contact investigations: lessons learned in North Carolina |
| Q36463383 | Intensified case-finding for latent tuberculosis infection among the Baltimore City Hispanic population |
| Q36998816 | Isoniazid therapy for Mycobacterium tuberculosis infection in HIV clinics, Los Angeles, California |
| Q38412531 | Latent Tuberculosis Infection Among Immigrant and Refugee Children Arriving in the United States: 2010. |
| Q42539032 | Latent tuberculosis infection among foreign-born persons: a prioritized approach |
| Q35787450 | Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries |
| Q36999773 | Molecular epidemiology of tuberculosis in foreign-born persons living in San Francisco |
| Q28391275 | Mortality hazard and survival after tuberculosis treatment |
| Q45988272 | Moving toward tuberculosis elimination: implementation of statewide targeted tuberculin testing in Tennessee. |
| Q35943027 | Multicytokine detection improves latent tuberculosis diagnosis in health care workers |
| Q38192554 | Performance of QuantiFERON-TB Gold and tuberculin skin test relative to subjects' risk of exposure to tuberculosis |
| Q37572513 | Persistent latent tuberculosis reactivation risk in United States immigrants |
| Q50626332 | Positive Tuberculosis Blood Test as a Predictor of Health Status Among HIV-Infected Persons. |
| Q53423578 | Preventing Infectious Pulmonary Tuberculosis Among Foreign-Born Residents of the United States. |
| Q38797602 | Reactivation tuberculosis: role of surveillance |
| Q92126654 | Resource implications of the latent tuberculosis cascade of care: a time and motion study in five countries |
| Q64137320 | Screening for Latent Tuberculosis Infection Among HIV-Infected Medicaid Enrollees |
| Q40596209 | Serial testing for latent tuberculosis using QuantiFERON-TB Gold In-Tube: A Markov model |
| Q54237978 | The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review. |
| Q26752645 | The impact of migration on tuberculosis epidemiology and control in high-income countries: a review |
| Q41665632 | The impact of tuberculosis on health utility: a longitudinal cohort study |
| Q37997253 | The role of interferon-gamma release assay in tuberculosis control |
| Q90458491 | Tuberculosis - United States, 2019 |
| Q40208853 | Tuberculosis screening among HIV-infected patients: tuberculin skin test vs. interferon-gamma release assay. |
| Q38075591 | Tuberculosis screening in immigrants from high-prevalence countries: interview first or chest radiograph first? A pro/con debate |
| Q38019488 | Update in tuberculosis and nontuberculous mycobacterial disease 2011. |
| Q28073158 | Updates on the risk factors for latent tuberculosis reactivation and their managements |
| Q46159067 | Weakly positive tests and chronologic variation of the QuantiFERON assay: a retrospective appraisal of usefulness |
| Q35010340 | What patient factors predict physicians' decision not to treat latent tuberculosis infection in tuberculosis contacts? |
Search more.